Mereo BioPharma Group plc

For the period ended Dec 31, 2024. Filed Mar 26, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 26, 2025

MREO$0.28+0.9%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated balance sheets

	December 31,	December 31,
	2024	2023
Assets
Current assets:
Cash and cash equivalents	$69,802	$57,421
Prepaid expenses and other current assets	2,175	5,156
Research and development incentives receivables	2,786	1,183
Total current assets	74,763	63,760
Property and equipment, net	257	405
Operating lease right-of-use assets, net	727	1,245
Intangible assets, net	643	1,089
Total assets	$76,390	$66,499
Liabilities
Current liabilities:
Accounts payable	$2,440	$2,346
Accrued expenses	4,071	5,467
Convertible loan notes – current	5,535	—
Operating lease liabilities – current	707	652
Other current liabilities	1,095	1,021
Total current liabilities	13,848	9,486
Convertible loan notes – non-current	—	4,394
Warrant liabilities – non-current	821	412
Operating lease liabilities – non-current	187	906
Other non-current liabilities	565	764
Total liabilities	$15,421	$15,962
Commitments and contingencies (Note 17)
Shareholders’ Equity
Ordinary shares, par value £0.003 per share; 775,728,034 shares issued at December 31, 2024 (December 31, 2023: 701,217,089).	3,059	2,775
Treasury shares	—	(1,230)
Additional paid-in capital	539,642	486,107
Accumulated deficit	(462,883)	(419,630)
Accumulated other comprehensive loss	(18,849)	(17,485)
Total shareholders’ equity	60,969	50,537
Total liabilities and shareholders’ equity	$76,390	$66,499

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.